News & Media

News and features

3 December 2007

Interim Results for the six months ended 30 September 2007

16 October 2007

TEMPUS study of tonabersat commences

Minster Pharmaceuticals is pleased to announce that the first patients have entered the Company’s TEMPUS study in the US

4 October 2007

Change of Registered Office

Minster Pharmaceuticals plc (AIM: MPM) announces that the registered office

28 September 2007

Grant of Share Option To Director

Minster Pharmaceuticals plc (AIM: MPM) announces that, on 27 September 2007, Jerry Karabelas...

27 June 2007

Presentation at the 13th Congress of the International Headache Society

Minster Pharmaceuticals plc (AIM: MPM), the drug development company specialising in neurological...

22 June 2007

Annual Report and Financial Statements 2007

13 June 2007

Unaudited Preliminary Results for the year ended 31 March 2007

Minster Pharmaceuticals plc (AIM: MPM), the drug development company specialising in neurological and psychiatric disorders, is pleased to announce its preliminary results for the year ended 31 March 2007...

7 June 2007

Presentation at the American Headache Society Annual Scientific Meeting

Minster Pharmaceuticals plc (AIM: MPM), the drug development company specialising in neurological and psychiatric disorders, is pleased to announce that Professor Peter Goadsby...

18 May 2007

Conversion of Loan Note

The Board of Minster Pharmaceuticals PLC announces that, following receipt of a notice of intention to convert from a holder of £10,000 Unsecured Zero Coupon Convertible Loan Notes 2011

11 April 2007

Conversion of Loan Note

The Board of Minster Pharmaceuticals PLC announces that, following receipt of a notice of intention to convert from a holder of £80,000 Unsecured Zero Coupon Convertible Loan Notes 2011

27 March 2007

Board Appointments

Minster Pharmaceuticals plc (AIM: MPM), the drug development company specialising in neurological and psychiatric disorders, is pleased to announce the appointment of...

26 March 2007

Result of Extraordinary General Meeting

Minster Pharmaceuticals plc (AIM: MPM), the drug development company specialising in neurological and psychiatric disorders, is pleased to announce that...

2 March 2007

Fundraising of £17 million and Share Consolidation

Minster Pharmaceuticals plc (AIM: MPM), the drug development company specialising in neurological and psychiatric disorders, is pleased to announce a fundraising by...

9 January 2007

Positive Tonabersat Migraine Study Findings

Minster Pharmaceuticals plc (AIM: MPM), the drug development company specialising in neurological and psychiatric disorders, today updates the market...